Navigation Links
Nile Therapeutics to Present at Two Upcoming Investor Conferences
Date:11/3/2008

SAN FRANCISCO, Nov. 3 /PRNewswire-FirstCall/ -- Nile Therapeutics, Inc., (Nasdaq: NLTX), announced today that Peter Strumph, Chief Executive Officer, will present at the following upcoming investor conferences:

-- Rodman & Renshaw 10th Annual Healthcare Conference at 2:25 p.m. ET in the Kennedy II room on Monday, November 10, 2008 at The Palace Hotel in New York, NY.

-- Lazard Capital Markets 5th Annual Healthcare Conference at 9:00 a.m. ET on Wednesday, November 19, 2008 in the La Maisonette I room at The St. Regis Hotel in New York, NY.

Mr. Strumph will provide an overview of Nile and an update on its clinical development programs, including interim data from Nile's Phase 2a study for its lead compound, CD-NP, a novel chimeric peptide for the treatment of heart failure.

About Nile Therapeutics

Nile Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops innovative products for the treatment of cardiovascular disease and other areas of unmet medical need. Nile is initially focusing its efforts on developing its lead compound, CD-NP, a novel rationally designed chimeric peptide in clinical studies for the treatment of heart failure; 2NTX-99, a small molecule, pre-clinical, anti-atherothrombotic agent with nitric oxide donating properties; and CU-NP, a novel rationally designed natriuretic peptide. A key component of the company's strategy is to acquire the global rights to additional compounds to expand its portfolio. More information on Nile can be found at http://www.nilethera.com.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this press release regarding our strategy, future operations, outlook, milestones, the success of Nile's product development, future financial position, future financial results, plans and objectives of management are forward-looking statements. We may not actually achieve these plans, intentions or expectations and Nile cautions investors not to place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make. Various important factors that could cause actual results or events to differ materially from the forward-looking statements that we make are described in greater detail in the reports we file with Securities and Exchange Commission, including the "Risk Factors" section in Item 1 of the Form 10-KSB we filed with the Securities and Exchange Commission on March 27, 2008. Nile is providing this information as of the date of this press release and does not undertake any obligation to update any forward-looking statements as a result of new information, future events or otherwise.


'/>"/>
SOURCE Nile Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Arno Therapeutics to Present at the Rodman & Renshaw 10th Annual Healthcare Conference
2. Halozyme Therapeutics Begins Phase 2 Clinical Trial of Insulin With rHuPH20 in Type 1 Diabetic Patients
3. Halozyme Therapeutics Announces Conference Call on November 6 to Review Third Quarter Results
4. United Therapeutics Reports Third Quarter 2008 Financial Results
5. Arete Therapeutics Bolsters Management Team
6. Sirnaomics Receives SBIR Grant from NCI For Its Multi-Targeted Cancer siRNA Therapeutics
7. Laureate Pharma Announces Agreement with Tolera Therapeutics, Inc.
8. Nile Therapeutics to Present at the 7th Annual BIO Investor Forum
9. Nektar Therapeutics to Webcast R&D Day on November 12th
10. Amicus Therapeutics Announces Third Quarter 2008 Results Release Date
11. Sir Richard Sykes Joins BioCeramic Therapeutics as Chairman
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)...   Biocept, Inc . (NASDAQ: ... actionable liquid biopsy tests to improve the management ... its Target Selectorâ„¢ Circulating Tumor Cell platform demonstrated ... of actionable biomarkers in patients with metastatic breast ... Cannon Research Institute (SCRI), the research arm of ...
(Date:12/7/2016)... ... December 07, 2016 , ... Huffman Engineering, Inc. , ... Wonderware Certified System Integrator Partner. Huffman Engineering is the only Nebraska-based company ... System Integrator Partner certification gives customers confidence that our engineers are fully trained ...
(Date:12/7/2016)... CALGARY , Dec. 7, 2016 /PRNewswire/ - Zenith Capital Corp. ... update that will be presented at the Company,s Annual and ... Meeting of Shareholders will take place on Thursday, December 15, ... Ross Glenn Hall (Room EC1040), 4825 Mount Royal Gate ... am (MST). A notice of meeting and management information circular, ...
(Date:12/7/2016)... The report "Acrylic Processing Aid Market by Polymer Type (PVC), Fabrication ... - Global Forecast to 2026", published by MarketsandMarkets, the global market size was ... by 2026, registering an of CAGR of 6.2% between 2016 and 2026. ... ... MarketsandMarkets Logo ...
Breaking Biology Technology:
(Date:12/7/2016)... , Dec. 7, 2016   Veridium ... announced the appointment of new CEO James ... executive with decades of experience, has served in ... Cisco, where he specialized in expanding a pipeline ... technology portfolios. He most recently served as managing ...
(Date:12/6/2016)... 2016 Securus Technologies, a leading provider ... public safety, investigation, corrections and monitoring, and the ... five (5) year funding commitment by Securus to ... rehabilitation and reentry support to more inmates and ... 2004, the Prison Entrepreneurship Program (PEP) is an ...
(Date:12/2/2016)...   SoftServe , a global digital technology ... electrocardiogram (ECG) biosensor analysis system for continuous driver ... The smart system ensures device-to-device communication between ECG ... mobile devices to easily ,recognize, and monitor users ... technology advances, so too must the security systems ...
Breaking Biology News(10 mins):